CDKN2A and melanoma: A study based on 80 melanoma-prone families consisting of 402 melanoma patients and 713 non-affected family members from North America, Europe, and Australia was used by the Melanoma Genetics Consortium to calculate the lifetime projected risk of developing the disease in CDKN2A carriers (Bishop et al., 2002).